Latest Posts
What is the state’s position on private health and drug insurance? Lior Barak, Deputy Director-General of the…
“I am deeply concerned that the familiar drug insurance policy will be harmed unless changes are made.…
The grounds for outright rejection by HMO exceptions committees have been significantly narrowed, and budget considerations are…
To better understand global processes in health insurance, Hillel Damlin, CEO of Swiss Re Israel, presented at…
The pharmaceuticals market is evolving, and one of the current trends is a growing use of off-basket…